I. Bernard-Pierrot

The paper develops patient-derived xenografts (PDXs) for bladder and ureteral cancers, identifies molecular subtypes, and shows that combined FGFR/EGFR inhibition is more effective than single-agent therapy for FGFR3-mutant tumors.

The paper identifies super-enhancer networks regulating bladder cancer subtypes through transcription factors, showing their role in cell identity and inflammatory response suppression.

This study shows FGFR3-S249C mutations drive luminal-like papillary bladder tumors in mice and correlate with male gender bias and AR activity in human tumors.

The paper identifies PPARγ as a tumor suppressor in basal bladder tumors and suggests therapeutic opportunities through PPARγ activation.